Scancell Holdings PLC

Company Profile

• Business description

  Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

• Contact

  Sanders Road
  Unit 202, Bellhouse Building
  Oxford Science Park
  OxfordOX4 4GD
  GBR

  T: +44 1865582066

  https://www.scancell.co.uk

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  30 April 2026

  Employees

  58